Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

RCT (n=468) found progression-free survival was significantly longer with sacituzumab govitecan than with single-agent chemotherapy (median 5.6 vs. 1.7 months; HR 0.41; 95% CI, 0.32 to 0.52; p<0.001), but myelosuppression and diarrhoea were more frequent.

SPS commentary:

Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen which is expressed in the majority of breast cancers, coupled to SN-38 (topoisomerase I inhibitor) through a proprietary hydrolyzable linker. In US, it was recently granted full approval for the treatment of locally advanced or metastatic triple-negative breast cancer after at least two prior therapies. In the EU, a Marketing Authorisation Application was validated by the European Medicines Agency in March 2021.

New England Journal of Medicine